Voyager Therapeutics, Inc.
Developing AAV gene therapies for neurological diseases like Alzheimer's, ALS, and Parkinson's.
VYGR | NDAQ
Overview
Corporate Details
- ISIN(s):
- US92915B1061
- LEI:
- Country:
- United States of America
- Address:
- 75 HAYDEN AVENUE, 2421 LEXINGTON
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
Voyager Therapeutics, Inc. is a biotechnology company dedicated to developing transformative neurogenetic medicines to treat and potentially cure severe neurological diseases. The company leverages human genetics to advance its pipeline, which includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and other central nervous system disorders. A core component of its scientific approach is the proprietary TRACER™ AAV capsid discovery platform, which generates novel adeno-associated virus (AAV) capsids engineered for enhanced delivery of genetic therapies across the blood-brain barrier.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Voyager Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Voyager Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Voyager Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
